SVS:CA

Solarvest Launches World's First Organic DHA Omega-3 Fruit Gummy Drops for Children

(TheNewswire)



TheNewswire - December 21 st, 2020  -  Solarvest BioEnergy Inc. ("Solarvest", or the "Company") (TSXV:SVS), Solarvest, through it's 100% wholly owned subsidiary Eversea TM is pleased to announce plans to launch its Organic Omega-3 nutritional Gummy Fruit Drops for children after the year-end holiday break.  The fruit drop has been produced and passed quality control under high standards from our German contract manufacturer.  The final phase is to confirm the quality of the product after the logistics of shipping and packaging which is underway.  The Company's first of its kind nutritional gummy product will be an exceptional competitor in the large and rapidly growing gummy supplement market.  The organic gummy contains Solarvest's proprietary, certified organic, Omega-3 DHA powder, a sustainable, plant based powder designed for organic, vegetarian and vegan consumers.

The Company is actively working to add unique products to satisfy the demand for premium organic, Omega-3 and plant-based health products.  This first labelled product will soon commence sales in the USA and be available from the company's E-commerce web site ( www.eversea.ca ) and through Amazon. Eversea will be capable of providing organic oriented retailers with house branded products based on our patented ingredient (differentiation), so that they may take benefit from the extensive market demand for the product's unique characteristics, particularly for organic and vegan diets.

The company also announces the completion of its USA infrastructure and logistics system for order processing. Our west coast distribution point is located close to the primary and most important market for organic and plant based supplements/foods.  In addition this strategic location is close to organic food processors, sustainable oriented consumers and the organic baby food market.  The facility is capable of nation-wide distribution.

The Eversea Omega-3 powder is USDA and EU Organic Certified and produced from the Company's sustainable, proprietary process.  Gerri Greenham, CEO, notes that, "Our omega 3's are sustainable because they are expressed in algae and grown in controlled facilities which eliminates the need to harvest marine species.  Our technology produces an organically certified, highly bioavailable long-chain Omega-3 that cannot be produced by common plant species such as flaxseed or hemp which only contain ALA Omega-3.  Our customers are buying a product to improve health so they want an organic product which has a clean label of ingredients."  The Company also intends to sell the powder supplement to organic food processors and marketers, such as baby food suppliers, to facilitate the development of enhanced patent-protected products. The Company also intends to pursue other premium animal health applications such as high Omega-3 eggs, pet supplements and food. "

Eversea has also initiated a second product run with its German-based organically certified manufacturer to supplement inventory levels domestically and initiate international sales. Recognizing that Eversea's organically certified product holds a competitive advantage with several differentiating factors focused on sustainability, environmental conservation, bioavailability and purity, the Company will be able to deliver alternatives for the adult, seniors, infant formula and maternity markets to complement its adolescent offering.

Market Overview

"The EPA and DHA omega-3 finished product market size reached US$44.2 billion in 2019. as stated in the  2020 Global EPA &DHA Finished Goods Report.  Market dynamics and new product development are driving increased growth in certain product categories and across several regions of the world, leading the global EPA and DHA consumer product market to a projected annual growth rate of 6.1% for 2020–2021".

"The global gummy vitamins market size is estimated to be valued at USD 5.9 billion in 2020 and projected to reach USD 10.6 billion by 2025, recording a CAGR of 12.5%, in terms of value" as stated by Reportlinker in Oct 27, 2020 PRNewswirepress release.

About Solarvest

Solarvest BioEnergy Inc. is an algae biologics company whose production platform provides it with an extremely flexible system capable of producing numerous products from Omega 3 fatty acids to human therapeutic proteins. The company has successfully demonstrated the expression of BMP, a high value therapeutic protein, viral antigens (immune stimulating proteins), and Cecropins (antimicrobial peptide/protein). The company has initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.

For further information contact:

Email: invest@solarvest.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties.  Actual events or results could differ materially from the Company's expectations and projections.

Copyright (c) 2020 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

The Conversation (0)
  BPH Global Ltd

120-Day Business Development Plan

The Board of BPH Global Ltd (ASX: BP8) (Company) announces that the Company’s CEO Matthew Leonard and CFO Chow Yee Koh are currently travelling in Malaysia and China for a series of meetings over a 2–3- week period commencing last week. The CEO and CFO will be joined by China-based Company Director Michael Huang for strategic meetings in Malaysia and China.

Keep reading...Show less
  BPH Global Ltd

BP8 to Expand Seaweed R&D Activities into Essential Mineral Extraction Utilising AI Search Technology; Carbon Credits

The Board of BPH Global Ltd (ASX: BP8) (Company) is pleased to announce that the Company is expanding the nature of its business to include the following projects:

Keep reading...Show less
Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") announces a significant achievement in its quest to transform the skincare industry. Its subsidiary, TFChem, has successfully received formulations for its eagerly awaited GlycoProteMim™ based anti-aging serum from its formulation partner, Global Beauty Consulting (GBC). This marks a crucial step in Sirona Biochem's plan to offer innovative skincare solutions.

The chosen formulation will not only define the brand but also lay the foundation for a broader range of products. The team is in the process of selecting the precise formulation that will undergo standard safety evaluations and be used in the upcoming clinical trial. This is in preparation for the planned product launch in early 2025, ensuring compliance with regulatory standards in the European, US, and Canadian markets.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
double helix molecule with word "etf"

5 Small Biotech ETFs to Watch (Updated 2024)

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to gain leverage in multiple biotech companies via one investment vehicle.

The life science sector can certainly be risky, and ETFs are a good way to enter more safely than by investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.

Below the Investing News Network takes a look at five small biotech ETFs for investors to consider. They were selected using ETFdb.com, and their total assets under management (AUM) were under US$100 million as of March 8, 2024. All other figures were also current as of that date. Read on to learn more about these investment vehicles.

Keep reading...Show less

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® AT AAD 2024

SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis

Late-Breaking Phase 3 Study of Otezla in Palmoplantar Pustulosis Achieves Primary and Secondary Endpoints at 16 Weeks

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Collage with hands holding shiny DNA molecule on blue background.

5 Biggest Biotechnology ETFs in 2024

Investing in the biotech industry can be a long road to gains given the sector’s volatility.

Even with a good understanding of the system, no one can predict which treatment, device or therapy will give the biggest return, making biotech exchange-traded funds (ETFs) a more secure option than individual biotech stocks.

An ETF is a relatively safe investment route that can minimize losses while offering exposure to multiple companies instead of focusing on the gains and losses of a single biotech stock. With that in mind, here’s a brief look at the five top biotechnology ETFs by total assets. Data was sourced from ETFdb.com on March 1, 2024, and all data was current as of that time.

Keep reading...Show less

Latest Press Releases

Related News

×